Biểu đồ giá cổ phiếu URGN
URGN Thu nhập
Urogen Pharma Ltd
$46.43
16.3%
$6.5
Khi đóng cửa: Aug 05, 16:00:00 GMT-4
$46.08
-0.75%
$-0.35
Phiên trước giờ: Aug 06, 10:35:26 GMT-4
Quay lại
Urogen Pharma Ltd (URGN) Thu nhập
Thống kê chính
Giá đóng cửa trước
$39.92
Giá mở cửa
$42.17
Phạm vi ngày
$40.41 - $47.8
Phạm vi 52 tuần
$14 - $46.08
Khối lượng
2.4M
Khối lượng trung bình
782.7K
Tỷ suất cổ tức
--
EPS (TTM)
-2.75
Vốn hóa thị trường
$2.2B
URGN là gì?
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. The firm is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
